Stuart A. Weinzimer, United States of America

Yale University Pediatric Endocrinology
Stuart A Weinzimer MD, is Professor of Pediatrics at the Yale University School of Medicine, Clinical Professor at the Yale School of Nursing, and Attending Pediatric Endocrinologist at the Yale-New Haven Children’s Hospital. He graduated summa cum laude from Yale University with a bachelor’s degree in Molecular Biochemistry and Biophysics, earned his medical degree at the Albert Einstein College of Medicine, and completed pediatric residency and pediatric endocrinology fellowship training at the Children’s Hospital of Philadelphia. He has been a Principal Investigator for multiple NIH-funded clinical trials of closed-loop insulin delivery and the Diabetes Research in Children Network. He has over 250 peer-reviewed publications, reviews and book chapters, and and has been conducting studies on diabetes technologies for 20 years. His current research projects focus on the development, evaluation, and implementation of automated insulin delivery systems, the effects of dysglycemia on brain structure and function in children, and behavioral strategies to facilitate physical activity in youth with diabetes. When he is not working he may usually be found close to a piano.

Presenter of 1 Presentation

PARALLEL SESSION

DEBATE: In the era of remote visits – do we still need A1c measures - CON

Abstract

Abstract Body

Hemoglobin A1c has been the gold standard metric to assess glycemic control in people with type 1 diabetes since the Diabetes Control and Complications Trial and has subsequently been adopted to other forms of diabetes, as well as for the diagnosis of diabetes. However, the rapidly increasing use of continuous glucose monitoring (CGM) has enabled clinicians to assess metrics of glycemia more directly; and with the growing popularity of telemedicine, driven most urgently in the past year by the COVID pandemic, the role of A1c as a clinically important measure has been questioned. In this brief debate, we will discuss the relative merits and limitations of A1c and CGM, and whether continuing use of A1c measurement in clinical care is still warranted.

Hide